3-(1H-tetrazol-5-yl)-benzenamine hydrochloride | 145878-38-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 3-(1H-tetrazol-5-yl)-benzenamine hydrochloride
• 英文别名: 5-(3-aminophenyl)tetrazole hydrochloride；3-tetrazolylaniline hydrochloride；3-(1H-tetrazol-5-yl) benzenamine hydrochloride；5-(3-Aminophenyl)tetrazole, hydrochloride salt；3-(1H-tetrazol-5-yl)benzenamine hydrochloride；3-(2H-tetrazol-5-yl)-phenylamine hydrochloride；3-(2H-tetrazol-5-yl)aniline;hydrochloride
• CAS: 145878-38-2
• 化学式: C₇H₇N₅*ClH
• 分子量: 197.627
• InChiKey: UWIGBDRMNMPNHS-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.87
• 重原子数：
  13
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  80.5
• 氢给体数：
  3
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  3-(1H-tetrazol-5-yl)-benzenamine hydrochloride 在 三乙胺 作用下， 以 四氢呋喃 为溶剂， 生成 1-[1-(2-toluoylmethyl)-2-oxo-5-pivaloyl-1,3,4,5-tetrahydro-2H-1,5-benzodiazepin-3-yl]-3-[3-(N,N-dimethylamino)phenyl]urea
  参考文献：
  名称：

  1,5 Benzodiazepine derivatives

  摘要：

  公式（I）所代表的1,5-苯二氮卓衍生物，其盐以及含有其作为活性成分的药物：这些化合物表现出优秀的胃泌素和/或CCK-B受体拮抗作用，并可用作治疗胃溃疡和胃肠道运动障碍的药物。

  公开号：

  US06239131B1
• 作为产物：
  描述：

  5-(3-硝基苯基)-2H-四唑 在 钯 作用下， 以 盐酸 、 乙醇 为溶剂， 以71%的产率得到3-(1H-tetrazol-5-yl)-benzenamine hydrochloride
  参考文献：
  名称：

  Benzodiazepine derivatives, compositions containing them and their use in therapy

  摘要：

  公式(I)的化合物，以及其盐和前药，其中：R¹代表可选地取代的C₁₋₆烷基或C₃₋₇环烷基；R²代表可选地取代的苯基或吡啶基团；R³代表C₁₋₆烷基或卤素；R⁴代表C₃₇环烷基；X是0、1、2或3；是CCK和/或胃泌素拮抗剂。它们及其组合物因此在治疗中是有用的。

  公开号：

  EP0514133A1

文献信息

• Benzodiazepine derivatives, compositions containing them and their use in therapy
  申请人：MERCK SHARP & DOHME LTD.

  公开号：EP0514133A1

  公开（公告）日：1992-11-19

  Compounds of formula (I), and salts and prodrugs thereof wherein:    R¹ represents optionally substituted C₁₋₆alkyl or C₃₋₇cycloalkyl;    R² represents an optionally substituted phenyl or pyridyl group;    R³ represents C₁₋₆ alkyl or halo;    R⁴ represents C₃₋₇ cycloalkyl;    X is 0, 1, 2 or 3; are CCK and/or gastrin antagonists. They and compositions thereof are therefore useful in therapy.

  公式(I)的化合物，以及其盐和前药，其中：R¹代表可选地取代的C₁₋₆烷基或C₃₋₇环烷基；R²代表可选地取代的苯基或吡啶基团；R³代表C₁₋₆烷基或卤素；R⁴代表C₃₇环烷基；X是0、1、2或3；是CCK和/或胃泌素拮抗剂。它们及其组合物因此在治疗中是有用的。
• Tetrahydro-1H-benzazepinones and hexahydroazepinones as selective
  申请人：Pfizer Inc.

  公开号：US05618811A1

  公开（公告）日：1997-04-08

  This invention relates to compounds of formula (I) wherein R.sup.1, R.sup.2, R.sup.3, R.sup.4 and X are as defined in the application. These compounds are CCK-B receptor antagonists and are useful in the treatment and prevention of central nervous system and gastrointestinal disorders. ##STR1##

  这项发明涉及式(I)的化合物，其中R.sup.1、R.sup.2、R.sup.3、R.sup.4和X如申请中所定义。这些化合物是CCK-B受体拮抗剂，可用于治疗和预防中枢神经系统和胃肠道疾病。
• Method of inducing cholecystokinin agonist activity using 1,4-
  申请人：Glaxo Wellcome Inc.

  公开号：US05795887A1

  公开（公告）日：1998-08-18

  A method of inducing a Cholescystokinin-A receptor agonist response in a mammal by administering a compound of formula (I), ##STR1## where R.sup.1 is C.sub.1 -C.sub.6 alkyl, C.sub.3-6 cycloalkyl, phenyl, or substituted phenyl; R.sup.2 is C.sub.3-6 alkyl, C.sub.3-6 cycloalkyl, C.sub.3-6 alkenyl, benzyl, phenylC.sub.1-3 alkyl or substituted phenyl; or NR.sup.1 R.sup.2 together form 1,2,3,4-tetrahydroquinoline or benzazepine mono-, di-, or trisubstituted independently with C.sub.1-6 alkyl, C.sub.1-6 alkoxy or halogen substituents; n is an integer selected from the grouping consisting of 0,1,2 or 3; p is the integer 0 or 1; q is the integer 0 or 1; r is the integer 0 or 1, provided that when q is 0 then r is 0; R.sup.3, R.sup.4, R.sup.5 and R.sup.8 are selected from a variety of substituents; X is nitrogen, nitroso or R.sup.8 ; m is an integer selected from the group consisting of 0, 1, 2 or 3; Y and Z are hydrogen or halogen, novel intermediates, a pharmaceutical composition for treating obesity, gall bladder stasis, disorders of pancreatic secretion, methods for such treatment and processes for preparing compounds of formula (I).

  通过向哺乳动物投与公式(I)的化合物，诱导胆囊收缩素A受体激动剂反应的方法，其中R.sup.1为C.sub.1 -C.sub.6烷基，C.sub.3-6环烷基，苯基或取代苯基；R.sup.2为C.sub.3-6烷基，C.sub.3-6环烷基，C.sub.3-6烯基，苄基，苯基C.sub.1-3烷基或取代苯基；或NR.sup.1 R.sup.2一起形成1,2,3,4-四氢喹啉或苯并二氮杂环烷单取代、二取代或三取代，独立地用C.sub.1-6烷基，C.sub.1-6烷氧基或卤素取代基取代；n为从0,1,2或3中选择的整数；p为整数0或1；q为整数0或1；r为整数0或1，条件是当q为0时，r为0；R.sup.3，R.sup.4，R.sup.5和R.sup.8从各种取代基中选择；X为氮，亚硝基或R.sup.8；m为从0,1,2或3中选择的整数；Y和Z为氢或卤素，新的中间体，用于治疗肥胖、胆囊瘀滞、胰腺分泌紊乱的药物组合物，用于该治疗的方法和制备公式(I)化合物的过程。
• Use of 1,5-benzo\x9bb!1,4-diazepines to control gastric emptying
  申请人：Glaxo Wellcome Inc.

  公开号：US05910495A1

  公开（公告）日：1999-06-08

  A method of controlling gastric emptying in patients having an early non-insulin-dependent diabetic condition and exhibiting rapid gastric emptying comprising the administration of an effective gastric emptying controlling amount of a compound of Formula (I) ##STR1## or a physiologically acceptable salt or solvate thereof.

  一种控制患有早期非胰岛素依赖型糖尿病病情且胃排空迅速的患者胃排空的方法，包括给予化合物的有效胃排空控制量，该化合物为下式（I）的化合物或其生理上可接受的盐或溶剂。
• Benzodiazepine derivatives, compositions containing them and their use
  申请人：Merck Sharp & Dohme Ltd.

  公开号：US05451582A1

  公开（公告）日：1995-09-19

  Compounds of formula (I), and salts and prodrugs thereof ##STR1## wherein: R.sup.1 is H, certain optionally substituted C.sub.1.6 alkyl, or C.sub.3-7 cycloalkyl; R.sup.2 is (CH.sub.2).sub.q -tetrazolyl optionally substituted in the tetrazole ring by C.sub.1-4 alkyl, (CH.sub.2).sub.q -imidazolyl (where q is 0, 1, 2 or 3), CONHSO.sub.2 R.sup.9, SO.sub.2 NHCOR.sup.9 (where R.sup.9 is C.sub.1-6 alkyl, optionally substituted aryl or trifluoromethyl). SO.sub.2 NHR.sup.10 (where R.sup.10 is a nitrogen containing heterocycle), cyclopropyl or (CH.sub.2), CO.sub.2 H, where n is 1 or 2; R.sup.3 is C.sub.1-6 alkyl, halo or NR.sup.6 R.sup.7 ; R.sup.4 is C.sub.1-7 straight or branched chain alkyl; and x is 0, 1, 2 or 3; are CCK and/or gastrin receptor antagonists. They and compositions thereof are useful in therapy.

  式(I)的化合物，以及其盐和前药##STR1##其中：R.sup.1是H，某些可选择地取代的C.sub.1.6烷基，或C.sub.3-7环烷基；R.sup.2是(CH.sub.2).sub.q-四唑基，四唑环可选择地被C.sub.1-4烷基取代，(CH.sub.2).sub.q-咪唑基（其中q为0, 1, 2或3），CONHSO.sub.2 R.sup.9，SO.sub.2 NHCOR.sup.9（其中R.sup.9是C.sub.1-6烷基，可选择地取代的芳基或三氟甲基）。SO.sub.2 NHR.sup.10（其中R.sup.10是含氮杂环），环丙基或(CH.sub.2)，CO.sub.2 H，其中n为1或2；R.sup.3是C.sub.1-6烷基，卤素或NR.sup.6 R.sup.7；R.sup.4是C.sub.1-7直链或支链烷基；x为0, 1, 2或3；均为CCK和/或胃泌素受体拮抗剂。它们及其组合物在治疗中有用。